Ocean Biomedical, Inc.

OCEA

US67644C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-09 pm EST			5-day change	1st Jan Change
0.6999 ^USD	+0.82%		-1.56%	+6.05%

Nov. 25	Ocean Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Nov. 25	Ocean Biomedical, Inc. Auditor Raises 'Going Concern' Doubt	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Ocean Biomedical, Inc.

Ocean Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Nov. 25	CI
Ocean Biomedical, Inc. Auditor Raises 'Going Concern' Doubt	Nov. 24	CI
Ocean Biomedical, Inc. Announces Chief Executive Officer Changes	Oct. 29	CI
Ocean Biomedical, Inc. Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and Its Ability to Inhibit Anti-Tumor and Related Tissue Remodeling Responses	Oct. 01	CI
Ocean Biomedical, Inc. Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms	Aug. 27	CI
Virion Therapeutics, LLC announced that it has received $0.96 million in funding from Ocean Biomedical, Inc.	Aug. 20	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) added to Russell Microcap Growth Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 Value Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2000 Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000E Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2500 Value Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) added to Russell 3000E Growth Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2000 Value Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000E Value Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 2500 Index	Jun. 30	CI
Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 Index	Jun. 30	CI
Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	May. 30	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Apr. 15	CI
Ocean Biomedical, Inc. Appoints Amy Griffith as Director	Mar. 08	CI
Ocean Biomedical, Inc. Announces CFO Changes	Mar. 04	CI

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

Employees

Sector

Biotechnology & Medical Research

More about the company